AzTrials
AzTrials

Healthy VolunteersMEG-AGINGNCT04036162

Spatial and Dynamic Characterization of Brain Activity for Language and Posture (Verticality) During Normal Aging. Magnetoencephalography (MEG) Study (MEG-AGING)

A study testing Cognitive tasks in people with Healthy Volunteers, run by University Hospital, Grenoble at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Depending on the point of view, different definitions of aging have been proposed. Thus, at the biological level, aging corresponds to a natural physiological process that leads to the progressive degeneration of cells and the slowing down of the vital functions of a living organism. Read more about this study

Who is it for?
Ages 25 to 85 yearsHealthy volunteers can take part
Conditions the study is for
Healthy Volunteers
What is being tested?
Cognitive tasks
Could I receive a placebo?
No, everyone receives an active treatment
How many people
24 participants
Where
1 siteFrance
Study dates
1 Oct 2019to 22 Jun 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 85 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Healthy volunteers from 25 to 85 years old : young group (25-49 years) / aged group (50 to 85 years)
  • Right-handed
  • Signed informed consent
  • French mother tongue
  • Speaking fluent French
  • Normal or corrected view
  • Medical examination conducted prior to participation in the trial
  • Registered in the French social security scheme

Who cannot join

  • Contraindication to Magnetoencephalography (MEG) and/or Magnetic resonance imaging (MRI) : implanted material, claustrophobia,…
  • Generally severe condition: cardiac, respiratory, hematological, kidney, liver, cancer
  • Regular use of anxiolytics, sedatives, antidepressants, neuroleptics
  • Psychiatric pathology characterized
  • Alcohol ingestion before the exam
  • All categories of protected persons (Pregnant or lactating women, persons subject to a legal protection measure, persons deprived of their liberty by judicial or administrative decision)
Show all 9Show fewer
  • Alcohol ingestion before the exam
  • Participation in other ongoing clinical trial with exclusion period or in the previous week
  • Score MINI MENTAL STATE EXAMINATION (MMSE) < 24

Trial locations and contacts

1 site in 1 country.

France1 site
  • CHUGA

    Grenoble, 38000

Other trials in France

About this study

Depending on the point of view, different definitions of aging have been proposed. Thus, at the biological level, aging corresponds to a natural physiological process that leads to the progressive degeneration of cells and the slowing down of the vital functions of a living organism. More generally, aging is a multifactorial and multidimensional process that occurs at the cognitive, social, biological or psychological level.

The primary objective of this study is to evaluate the balance between activation (Task-Positive Network : TPN-Language, L, TPN-Verticality, V) and rest (Task-Negative Network : TNN) activity during normal aging, in two domains (language and posturo-spatial perception of verticality).

Read the detailed description

From a cognitive point of view, although healthy older people become slower to analyze information, they remain just as accurate as young adults in performing different cognitive tasks. This necessarily implies compensation processes, with new cognitive strategies and a restructuring of the brain networks underlying these processes. These compensatory phenomena are known under the general name of neurocognitive reserve.

Specific functions such as language, visuospatial skills, motor control, posture, or memory, are affected in a very variable way among the elderly. This variability involves multiple cognitive profiles rather than just one form of aging. Indeed, healthy aging can be defined cognitively in two ways, as a homogeneous or rather heterogeneous process. According to the homogeneous hypothesis of aging, the behavioral, cognitive and brain-like manifestations are similar among the elderly, without differentiation between functions. In other words, according to this hypothesis, aging would affect all the elderly and cognitive processes in the same way. Conversely, according to the heterogeneous hypothesis, significant differences should be revealed between individuals and in the same individual according to different cognitive processes. This heterogeneity is explained by multiple factors (genetic, environmental, societal, educational, or lifestyle). If neuropsychological tests or behavioral experiments (and performance of the task) allow to identify rather easily the differences encountered among the elderly in terms of cognitive heterogeneity, this differential activity at the cerebral level is more difficult to highlight. Functional neuroimaging methods and techniques can provide a pathway for this purpose, to provide both spatial information (involved brain regions) and temporal information (dynamics of brain activation) when performing cognitive tasks or when the rest period.

In this context, the magnetoencephalography (MEG) method is a preferred technique that can provide all these types of information on brain activity. Two types of networks can therefore be recorded : task-positive network (TPN) activated when the participant is involved in a task (in this project, language and posture / verticality), and task-negative network (TNN) specific to the state of rest , represented by regions that are called "deactivated". These two networks will therefore be characterized in the study by the following parameters: (a) network: set of regions involved; (b) temporal dynamics of their activity, and (c) functional connectivity between the regions of TPN and TNN.

To answer the question of homogeneity vs. heterogeneity of cognitive cerebral aging, TPNs vs. TNN will be compared in a group of healthy young adults compared to a group of healthy elderly subjects. The comparison will be made for the three categories of parameters mentioned above (a-c).

Being tested
Cognitive tasks
Keywords
Aging, Task-Positive Network (TPN), Task-Negative Network (TNN), MagnetoEncephaloGraphy (MEG), Verticality, Language, Hemispheric asymmetry
Medical subject headings
Language

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Cognitive tasksBehavioural

    MagnetoEncephaloGraphy (MEG) records

Study groups in NCT04036162
Study groupRoleWhat they receive
Young groupExperimentalYoung Right-handed healthy volunteers
Receives: Behavioral: Cognitive tasks
Aged groupExperimentalAged Right-handed healthy volunteers
Receives: Behavioral: Cognitive tasks

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Balance between activation (TPN-Language, L, TPN-Verticality, V) and rest (TNN) activity during normal aging, in two domains (language and posturo-spatial perception of verticality) recorded by magnetoencephalography (MEG)

    Evoked and continuous magnetic fields recorded during both cognitive tasks and during the rest period

    Measured: 2 hours

Secondary outcomes (1)
  1. Correlation between neuropsychological scores and brain activation or functional connectivity parameters recorded by magnetoencephalography (MEG) depending on both domains studied

    Neuropsychological scores on tests for all participants :

    • frontal cognitive functioning
    • anxiety and/or depressive symptoms
    • executive functions
    • verbal intelligence
    • language

    Advanced analyses of cerebral activity as measured by MEG

    • frequency time analyses via spectral decomposition (induced brain rhythms)
    • functional and effective connectivity analysis through coherence, phase locking value, and Dynamic Causal Modelling measures

    Measured: 1 hour

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Jul 2019
  2. Study start1 Oct 2019
  3. Primary completion22 Jun 2021
  4. Study completion22 Jun 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Right-handed healthy volunteers
Masking
None (open label)
Enrolment
24 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04036162
Sponsor's protocol ID
38RC18.294
Other IDs
2019-A01065-52
Acronym
MEG-AGING
Status last verified
May 2022
First submitted
25 Jul 2019
Last updated
9 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Hoyau E, Roux-Sibilon A, Boudiaf N, Pichat C, Cousin E, Krainik A, Jaillard A, Peyrin C, Baciu M. Aging modulates fronto-temporal cortical interactions during lexical production. A dynamic causal modeling study. Brain Lang. 2018 Sep;184:11-19. doi: 10.1016/j.bandl.2018.06.003. Epub 2018 Jun 15.

    PubMed 29913316
  • Baciu M, Boudiaf N, Cousin E, Perrone-Bertolotti M, Pichat C, Fournet N, Chainay H, Lamalle L, Krainik A. Functional MRI evidence for the decline of word retrieval and generation during normal aging. Age (Dordr). 2016 Feb;38(1):3. doi: 10.1007/s11357-015-9857-y. Epub 2015 Dec 28.

    PubMed 26711670
  • Boudiaf N, Laboissiere R, Cousin E, Fournet N, Krainik A, Baciu M. Behavioral evidence for a differential modulation of semantic processing and lexical production by aging: a full linear mixed-effects modeling approach. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2018 Jan;25(1):1-22. doi: 10.1080/13825585.2016.1257100. Epub 2016 Nov 24.

    PubMed 27883290

Questions about this trial

What is this clinical trial studying?

A study testing Cognitive tasks in people with Healthy Volunteers, run by University Hospital, Grenoble at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Balance between activation (TPN-Language, L, TPN-Verticality, V) and rest (TNN) activity during normal aging, in two domains (language and posturo-spatial perception of verticality) recorded by magnetoencephalography (MEG) (time frame: 2 hours). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04036162, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2022.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
MEG-AGING Clinical Trial NCT04036162 | AzTrials